

# NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

## Nerviano Medical Sciences establishes its Scientific Advisory Board

**Nerviano, IT and Boston, Mass, 26 March, 2024** - Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS S.r.l., focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced the formation of their Scientific Advisory Board (SAB), with the appointments of David A. Barbie, MD and David Feltquate MD, PhD, two accomplished scientific and medical leaders in Oncology with significant expertise in immunotherapy, clinical development, and translational medicine. The SAB met today to review key aspects of the NMS clinical portfolio and are looking forward to additional scientific and clinical discussions.

*"We are proud to welcome our SAB members. These outstanding experts will provide scientific guidance and critical insight to ensure NMS novel therapeutics might make a meaningful impact on the lives of patients worldwide. I am highly honored that NMS will be guided by David Barbie and David Feltquate and look forward to working closely with them."* said Lisa Mahnke, MD, PhD, CMO of NMS, CEO and Managing Director of NMS-US.

## NMS and NMS-US Scientific Advisory Board Member Bios

### David A. Barbie, MD

Dr. Barbie is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute (DFCI) and an Associate Professor of Medicine at Harvard Medical School. He is also Associate Director of the Belfer Center for Applied Cancer Science, as well as an Associate Member of the Broad Institute. Dr. Barbie earned his undergraduate degree at Harvard College and M.D. degree at Harvard Medical School and was a Howard Hughes Medical Investigator Program Medical Student Research Fellow in Dr. Edward Harlow's laboratory at the MGH Cancer Center. He then completed an MGH internal medicine residency and chief medical residency, a Dana-Farber Partners Oncology fellowship, and performed his post-doctoral work in Dr. William Hahn's laboratory at DFCI and the Broad Institute. Currently, he is the principal investigator of his own laboratory at DFCI while also seeing patients in the Lowe Center for Thoracic Oncology.

### David Feltquate MD, PhD

Dr. Feltquate is currently the Chief Medical Officer at Palleon Pharmaceuticals. Prior to joining Palleon, he was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Before this, he held numerous leadership positions at Bristol-Myers Squibb including Head of Oncology Early Clinical Development and Development Leader for Ipilimumab/Nivolumab Life Cycle Management. As the Nivolumab Clinical Head, he was responsible for the clinical development of the first PD-1 inhibitor from proof of concept through initial registration in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Dr. Feltquate earned a BS in biology from MIT and an MD/PhD in Immunology from the University of Massachusetts Medical School. He completed Internal Medicine training and was Chief Resident at Dartmouth Hitchcock Medical Center and Medical Oncology training at the Memorial Sloan-Kettering Cancer Center.

# NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

## About Nerviano Medical Sciences

[Nerviano Medical Sciences](#) (NMS) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which originate from our industrially renowned kinase inhibitor drug discovery platform comprising an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies. Our kinase platform has enabled us to out-license IP rights on approved innovative medicines such as encorafenib and entrectinib and currently includes preclinical to clinical stage products, which are being developed both in house and with partners, including 4 proprietary clinical assets in Phase I/II studies. Moreover, the development of our payload linker platform allows an extension of our pipeline with innovative payload linkers for next generation ADC production.

NMS combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with a global vision and a broad range of expertise in drug discovery and development. We collaborate with academia and clinical investigators as well as industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. NMS signed a collaboration agreement with licensing option with Merck Healthcare KGaA for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293 and, more recently, signed out-licensing of the linker-payload technology to Solve Therapeutics, Inc. and Italfarmaco S.p.A. Also, NMS has out-licensed Onvansertib, a clinical stage PLK1 inhibitor, to Cardiff Oncology.

Media contact: Sidney Dung: [sidney.dung@nervianoms.com](mailto:sidney.dung@nervianoms.com)